Overview
NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults because Janssen did not provide an evidence submission.
Last reviewed: 30 October 2019
Next review: We will review this decision if the company decides to make a submission.